Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021
Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced it will present new treatment satisfaction data for its oral immunotherapy drug, PALFORZIA, at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 in Poland. The company will share updated treatment satisfaction data evaluated in its Phase 3, randomised, double-blind, placebo-controlled trial, PALISADE, and open-label follow-on trial, ARC004.
Patient-reported treatment satisfaction was evaluated over two years following daily treatment with PALFORZIA in a clinical trial setting using the Treatment Satisfaction Questionnaire for Medication (TSQM-9). Peanut allergic participants reported overall satisfaction with the effectiveness and convenience items, as well as the medication’s ability to treat their condition.
“Patient-centricity is an essential pillar of clinical development, and we look forward to presenting these encouraging patient satisfaction data,” said Andrew Oxtoby, President and Chief Executive Officer of Aimmune Therapeutics. “We know efficacy and safety remain the traditional, crucial endpoints assessed; however, true clinical and medical progress requires a deep understanding of the patient experience – what the patient values and needs for a positive outcome.”
Additional data to be presented at EAACI include an update on the ongoing Phase 3 ARC008 open-label study which is looks at longer-term safety in patients. The data collected by this study will help facilitate discussions around the longer-term safety with clinicians, peanut-allergic individuals, and their families.
Full details of the oral and poster presentations can be found below.
Title: Treatment satisfaction with continued oral immunotherapy for peanut allergy: results after 1, 1.5, and 2 years of daily therapy
Presenter: Katharina Blümchen, MD, University Hospital Frankfurt (Germany)
Session Title: OAS 01 New perspectives in allergen immunotherapy
Date/Time: July 10, 3:05-3:13pmCEST
Title: Longer-term safety outcomes of defatted powder of Arachis hypogaea L. semen (peanuts) in subjects from prior clinical trials (ARC008): a trial-in-progress and preliminary insights
Presenter: Kirsten Beyer, MD, University Hospital Charité (Germany)
Session title: ePoster Allergen Immunotherapy
Date/Time: July 10, 9am-8:30pm CEST
PALFORZIA was approved in December 2020 by the European Commission (EC) for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet. PALFORZIA may be continued in patients 18 years of age and older.
PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time. PALFORZIA is a rigorously developed, pharmaceutical-grade OIT for peanut allergy with a well-defined allergen profile to assure the consistency of every dose, from 0.5 mg (equivalent to approximately 1/600th of a peanut kernel) to 300 mg.
PALFORZIA is not intended for, and does not provide, immediate relief of allergic symptoms. Therefore, this medicinal product is not to be used for emergency treatment of allergic reactions, including anaphylaxis. Self-injectable adrenaline (epinephrine) must be available to the patient at all times.
Please see full summary of product characteristics at www.aimmune.co.uk/our-product.
Aimmune Therapeutics UK Ltd., a Nestlé Health Science company, is a biopharmaceutical company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases. For more information, please visit www.aimmune.co.uk.
About Nestlé Health Science
Nestlé Health Science (NHSc), a wholly owned subsidiary of Nestlé, is a globally recognised leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and vitamins, minerals and supplements (VMS) brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the way we approach the management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world who are committed to making a difference in people's lives, for a healthier today and tomorrow. www.nestlehealthscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+44 7940 594788
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors27.10.2021 18:46:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/ “We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelt
FiRa Consortium Hits Major Milestones in Ultra-Wideband Momentum27.10.2021 18:00:00 CEST | Press release
The FiRa™ Consortium, a catalyst for bringing leading innovators together to drive Ultra-Wideband (UWB) expansion, is today announcing two milestones in the market acceptance of UWB technology. The first is the launch of the initial phase of its certification program aimed at driving interoperability between UWB devices. At the same time, FiRa Consortium is announcing it has now surpassed 100 members, including all of the top handset manufacturers globally, plus market leaders across semiconductors, networking, secure access, and consumer technology. “UWB is fast becoming a pillar of wireless local connectivity technology alongside Wi-Fi and Bluetooth,” said Charlie Zhang, Board Chair of FiRa Consortium. “When combined with the membership momentum we are seeing, our certification program signifies that the market is prepared and ready for broad implementation of UWB across market sectors.” FiRa Consortium’s certification program is the first to provide baseline testing and certificatio
Mitsubishi Corporation Life Sciences to Accelerate Next Wave of Digital Transformation and Business Growth by Switching to Rimini Street Support27.10.2021 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Mitsubishi Corporation Life Sciences, a food ingredients manufacturer within Mitsubishi Corporation’s Food Industry Group, has switched to Rimini Street Support for its JD Edwards applications. Switching from the vendor’s support to Rimini Street has enabled the company to dramatically reduce its maintenance costs and free up internal resources for strategic initiatives. By freeing up critical resources – time, money and personnel – Mitsubishi Corporation Life Sciences is able to begin investing in its digital transformation initiatives for the next five to 10 years and establish a foothold for further business expansion, both locally and overseas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005
CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD27.10.2021 17:47:00 CEST | Press release
CURACLE, a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of Théa, Europe’s number one independent ophthalmic company with a 150-year history, for the development and commercialization of CURACLE’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD). Under the terms of the agreement, CURACLE will receive an upfront payment of $6 million and could receive up to an additional $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle CURACLE to receive up to $2 billion in total payments. Théa and CURACLE will closely collaborate on the clinical development of this novel oral drug. CURACLE will be responsible for the Phase I and II clinical studies with TOI
Everbridge Selected to Power the Nationwide Public Alert System for Spain27.10.2021 15:29:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today announced the selection by Spain to deploy its next-generation population alerting technology to help keep the country’s more than 120 million residents and visitors safe and informed in case of an emergency. Everbridge announced the contract award anonymously in a press release last month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005638/en/ Everbridge Selected to Power the Nationwide Public Alert System for Spain (Graphic: Business Wire) The new country-wide public alert system of Spain will include both Cell Broadcast coverage at the national level, as well as the publication of alerts via the Web and through mobile alerts, powered by Everbridge. The state-of-the-art alert system will reach 99% of the population of Spain, including 47 million residents and nearly 80 million annual v
Earnix Again Recognized Among INSURTECH100’s Most Innovative Global Companies27.10.2021 15:23:00 CEST | Press release
Earnix, a global provider of advanced rating, pricing, and product personalization solutions for insurers and banks, has been again listed in INSURTECH100, recognizing the world’s most innovative InsurTech companies. Each year, a panel of industry experts and analysts led by FinTech Global, a data and research firm, evaluates hundreds of companies in the insurance industry for their business acumen, technological advancements and potential to make a lasting impact on the industry globally. “The insurance industry is going through a transformational period and Earnix is enabling insurers to seize the biggest opportunities and prevail in the face of challenges. With our unparalleled experience, operational efficiency, robust automation, and innovative analytics, we are helping carriers deliver decisions with agility via fully personalized dynamic insurance. We are pleased to be recognized again and will continue to innovate on behalf of insurers and their customers,” said Udi Ziv, CEO at
Airship Names Thomas Butta Chief Strategy and Marketing Officer27.10.2021 15:05:00 CEST | Press release
Airship, the mobile app experience company, today announced Thomas Butta has joined its executive leadership team as Chief Strategy and Marketing Officer, reporting directly to CEO and president Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005300/en/ SaaS branding expert and veteran CMO Thomas Butta joins Airship as Chief Strategy and Marketing Officer (Photo: Business Wire) Butta brings over two decades of marketing leadership and brand positioning expertise, resulting in billions of dollars of enterprise value created through market leadership, strategic acquisitions and record-breaking IPOs. Prior to joining Airship, Butta was CMO at SignalFx, and before that Sprinklr, where he redefined brand value around software observability and customer experience management respectively, resulting in SignalFx’s acquisition by Splunk and Sprinklr’s subsequent public offering under the ticker symbol, CXM (NASDAQ).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom